

```

s neisseria?(2w)mening?
  64936 NEISSERIA?
  190418 MENING?
S9 21122 NEISSERIA?(2W)MENING?
?s s9(20n)noncovant?
  21122 S9
    0 NONCOVANT?
S10 0 S9(20N)NONCOVANT?
?s s9 not py>1994
>>>One or more prefixes are unsupported
>>> or undefined in one or more files.
Processed 10 of 31 files ...
Processing
Completed processing all files
  21122 S9
  3918648 PY>1994
S11 19969 S9 NOT PY>1994
?s s11(20n)(esherichia?)
  19969 S11
    431 ESHERICHIA?
S12 0 S11(20N)(ESHERICHIA?)
?s s11(10n)(outer?(4w)membran? or protein? or
Processing
Processing
Processing
Processing
Processed 10 of 31 files ...
Processing
Processing
Processed 20 of 31 files ...
Processing
Completed processing all files
  19969 S11
  1194324 OUTER?
  2462962 MEMBRAN?
  74978 OUTER?(4W)MEMBRAN?
  5532912 PROTEIN?
S13 2835 S11(10N)(OUTER?(4W)MEMBRAN? OR PROTEIN? )
?s s13(10n)outer?membran?protein?
Processing
Processed 10 of 31 files ...
Processing
Processed 20 of 31 files

```

10468201 BIOSIS Number: 96068201

IMMUNOGENICITY AND EFFICACY OF ORAL OR INTRANASAL SHIGELLA-FLEXNERI 2A AND SHIGELLA-SONNEI PROTEOSOME-LIPOPOLYSACCHARIDE VACCINES IN ANIMAL MODELS
ORR N; ROBIN G; COHEN D; ARNON R; LOWELL G H

MED. CROP, ISRAEL DEFENCE FORCE, MILITARY POST 02149, ISRAEL.

INFECT IMMUN 61 (6). 1993. 2390-2395. CODEN: INFIB

Full Journal Title: Infection and Immunity

Language: ENGLISH

Immunity against shigellosis has been shown to correlate with the presence of antibodies specific for Shigella lipopolysaccharide (LPS). We here propose a new candidate vaccine for shigellosis composed of purified Shigella flexneri 2a or Shigella sonnei LPS hydrophobically complexed with group C type 2b Neisseria meningitidis outer membrane protein proteosomes. Immunization of mice either orally or intranasally with this complex induced specific homologous anti-LPS antibodies in both intestinal and respiratory secretions as well as in sera. Strong anamnestic responses were found after two or three immunizations. LPS alone, alkaline-detoxified LPS, or alkaline-detoxified LPS complexes with proteosomes was not effective. Oral or intranasal immunization of guinea pigs with two or more doses of this proteosome-LPS vaccine elicited homologous protection against Shigella keratoconjunctivitis (Sereny test). These data demonstrate that proteosomes can be used as an effective mucosal vaccine delivery system and that orally or intranasally administered acellular vaccines can protect against Shigella infections.

Descriptors/Keywords: NEISSERIA-MENINGITIDIS MOUSE GUINEA-PIG HUMAN
RELEVANCE IMMUNOLOGIC-DRUG KERATOCONJUNCTIVITIS PROTECTION INTESTINAL
SECRETIONS RESPIRATORY SECRETIONS

Concept Codes:

- *14006 Digestive System-Pathology
- *22018 Pharmacology-Immunological Processes and Allergy
- *34504 Immunology and Immunochemistry-Bacterial, Viral and Fungal
- *36002 Medical and Clinical Microbiology-Bacteriology
- 10064 Biochemical Studies-Proteins, Peptides and Amino Acids
- 10066 Biochemical Studies-Lipids
- 10068 Biochemical Studies-Carbohydrates
- 12503 Pathology, General and Miscellaneous-Comparative (1970-)
- 12508 Pathology, General and Miscellaneous-Inflammation and Inflammatory Disease
- 12512 Pathology, General and Miscellaneous-Therapy (1971-)
- 13012 Metabolism-Proteins, Peptides and Amino Acids
- 16001 Respiratory System-General; Methods
- 16006 Respiratory System-Pathology
- 19001 Dental and Oral Biology-General; Methods
- 20006 Sense Organs, Associated Structures and Functions-Pathology
- 22005 Pharmacology-Clinical Pharmacology (1972-)
- 22031 Pharmacology-Sense Organs, Associated Structures and Functions
- 22100 Routes of Immunization, Infection and Therapy
- 22501 Toxicology-General; Methods and Experimental
- 28002 Laboratory Animals-General (1970-)
- 31000 Physiology and Biochemistry of Bacteria

Biosystematic Codes:

- 06507 Neisseriaceae (1992-)
- 06702 Enterobacteriaceae (1992-)
- 86215 Hominidae
- 86300 Caviidae
- 86375 Muridae

Super Taxa:

- Microorganisms; Bacteria; Eubacteria; Animals; Chordates; Vertebrates;
- Mammals; Primates; Humans; Nonhuman Vertebrates; Nonhuman Mammals;
- Rodents

Concept Codes:

- *10508 Biophysics-Membrane Phenomena
- *12512 Pathology, General and Miscellaneous-Therapy (1971-)
- *22005 Pharmacology-Clinical Pharmacology (1972-)
- *22018 Pharmacology-Immunological Processes and Allergy
- *31000 Physiology and Biochemistry of Bacteria
- *34504 Immunology and Immunochemistry-Bacterial, Viral and Fungal
- *34508 Immunology and Immunochemistry-Immunopathology, Tissue Immunology
- *36002 Medical and Clinical Microbiology-Bacteriology
- 10068 Biochemical Studies-Carbohydrates
- 22100 Routes of Immunization, Infection and Therapy

Biosystematic Codes:

- 04814 Gram-negative Facultatively Anaerobic Rods-Uncertain Affiliation (1979-)
- 05110 Neisseriaceae (1979-)
- 05514 Streptococcaceae (1979-)
- 86215 Hominidae

Super Taxa:

- Microorganisms; Bacteria; Animals; Chordates; Vertebrates; Mammals; Primates; Humans

?t s15/5/42,43,46,47,49

15/5/42 (Item 42 from file: 5)

DIALOG(R)File 5:BIOSIS PREVIEWS(R)

(c) 1996 BIOSIS. All rts. reserv.

6403369 BIOSIS Number: 85003890

MOLECULAR CLONING AND EXPRESSION OF NEISSERIA-MENINGITIDIS CLASS 1 OUTER MEMBRANE PROTEIN IN ESCHERICHIA-COLI K-12

BARLOW A K; HECKELS J E; CLARKE I N

DEP. MICROBIOLOGY, UNIV. SOUTHAMPTON MED. SCH., SOUTHAMPTON GENERAL HOSP., SOUTHAMPTON SO9 4XY, UNITED KINGDOM.

INFECT IMMUN 55 (11). 1987. 2734-2740. CODEN: INFIB

Full Journal Title: Infection and Immunity

Language: ENGLISH

A genomic library of meningococcal DNA from a clinical isolate of *Neisseria meningitidis* was constructed in the expression vector .lambda.gt11. Outer membrane complex was prepared from the same strain and used to immunize rabbits to raise polyclonal anti-outer membrane complex serum. The amplified library was probed with this polyclonal serum, and seven expressing recombinants were isolated; further investigations indicated these to be identical. The expressed meningococcal gene in these recombinants was fused to vector B-galactosidase and shown to encode meningococcal gene in these recombinants was fused to vector .beta.-galactosidase and shown to encode epitopes present on the 42-kilodalton class 1 outer membrane protein. Estimation of the size of the recombinant fusion protein suggests that up to 40 kilodaltons of protein-coding sequence is present. The .lambda.gt11 recombinant contains a 3.4-kilobase DNA insert, which has been recloned into a plasmid and characterized by restriction endonuclease analysis. A restriction fragment from the insert, representing the protein-coding region hybridizes to a single 2.2-kilobase *Xba*I fragment from the homologous strain and to similar-sized *Xba*I fragments in other strains of meningococci, expressing antigenically distinct class I proteins.

Concept Codes:

- *10064 Biochemical Studies-Proteins, Peptides and Amino Acids
- *10508 Biophysics-Membrane Phenomena
- *30500 Morphology and Cytology of Bacteria
- *31000 Physiology and Biochemistry of Bacteria
- *31500 Genetics of Bacteria and Viruses
- 10052 Biochemical Methods-Nucleic Acids, Purines and Pyrimidines
- 10062 Biochemical Studies-Nucleic Acids, Purines and Pyrimidines
- 10506 Biophysics-Molecular Properties and Macromolecules

complexed to group B polysaccharide of *N. meningitidis* is described. These complexes, low in nucleic acid and lipopolysaccharide content, were immunogenic in mice with induction of humoral antigroup B and antiprotein responses. Immunized mice were also protected against challenge with *N. meningitidis* group B strains of the same or a different type from that used for vaccination. Both immunity and protection were enhanced when the mice received a secondary immunization with the protein-polysaccharide complex. Additional data have shown the capacity of purified B polysaccharide to induce immunological memory, even though it is incapable of inducing a humoral response when given alone.

Descriptors/Keywords: HUMORAL RESPONSE

Concept Codes:

- *13012 Metabolism-Proteins, Peptides and Amino Acids
- *22018 Pharmacology-Immunological Processes and Allergy
- *34504 Immunology and Immunochemistry-Bacterial, Viral and Fungal
- *36002 Medical and Clinical Microbiology-Bacteriology
- 10064 Biochemical Studies-Proteins, Peptides and Amino Acids
- 10068 Biochemical Studies-Carbohydrates
- 10508 Biophysics-Membrane Phenomena
- 31000 Physiology and Biochemistry of Bacteria
- 34502 Immunology and Immunochemistry-General; Methods

Biosystematic Codes:

- 05110 Neisseriaceae (1979-)
- 86375 Muridae

Super Taxa:

Microorganisms; Bacteria; Animals; Chordates; Vertebrates; Nonhuman
Vertebrates; Mammals; Nonhuman Mammals; Rodents

15/5/47 (Item 47 from file: 5)
DIALOG(R)File 5:BIOSIS PREVIEWS(R)
(c) 1996 BIOSIS. All rts. reserv.

4110123 BIOSIS Number: 76059974

PREPARATION AND PHYSICOCHEMICAL AND IMMUNOLOGICAL CHARACTERIZATION OF
POLY SACCHARIDE OUTER MEMBRANE PROTEIN COMPLEXES OF NEISSERIA-MENINGITIDIS
BEUVERY E C; MIEDEMA F; VAN DELFT R W; HAVERKAMP J; LEUSSINK A B; TERPENA
K S; TE PAS B J; TIESJEMA R H

RIJKSINSTITUUT VOLKSGEZONDHEID, 3720 BA BILTHOVEN.

INFECT IMMUN 40 (1). 1983. 369-380. CODEN: INFIB

Full Journal Title: Infection and Immunity

Language: ENGLISH

A crude complex containing group C polysaccharide, outer membrane proteins and lipopolysaccharide (LPS) was isolated from the cell-free culture liquid of *N. meningitidis* serogroup C, serotype 2a. Group C polysaccharide and LPS were removed from this complex, resulting in an outer membrane complex and a purified complex, respectively. Analysis by EM showed the outer membrane origin of the crude complex and the outer membrane complex; such a structure was absent in the purified complex. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis patterns of the 3 complexes were identical. Pyrolysis-mass spectrometry data correlated well with those obtained by the biochemical assays and suggested a low LPS content in the purified complex and a low polysaccharide content in the outer membrane complex. The purified complex was nonpyrogenic and was prepared with the same yield as that of purified polysaccharide. The immunogenic activities of the complexes were studied in mice. The antibodies were measured by the enzyme-linked immunosorbent assay and the bactericidal antibody assay. All complexes induced IgG antibodies to group C polysaccharide and LPS resulted in a reduction of the immunogenic activities of outer membrane complex and purified complex, respectively. A 2nd dose of all complexes produced a clear booster effect of both antibody responses. The antibodies were bactericidal.

Descriptors/Keywords: MICE LIPO POLY SACCHARIDE NONPYROGENIC IMMUNO
GLOBULIN ANTIBODIES SEROTYPE ANTIGEN CLEAR BOOSTER EFFECT

Concept Codes:

15/5/55 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 1996 Elsevier Science B.V. All rts. reserv.

5364321 EMBASE No: 83115928

Preparation and physicochemical and immunological characterization of polysaccharide-outer membrane protein complexes of *Neisseria meningitidis* Beuvery E.C.; Miedema F.; Van Delft R.W.; et al.

Rijksinst. Volksgezond., 3720 BA Bilthoven NETHERLANDS
INFECT. IMMUN. (USA), 1983, 40/1 (369-380) CODEN: INFIB
LANGUAGES: ENGLISH

A crude complex containing group C polysaccharide, outer membrane proteins, and lipopolysaccharide (LPS) was isolated from the cell-free culture liquid of *Neisseria meningitidis* serogroup C, serotype 2a. Group C polysaccharide and LPS were removed from this complex, resulting in an outer membrane complex and a purified complex, respectively. Analysis by electron microscopy showed the outer membrane origin of the crude complex and the outer membrane complex, whereas such a structure was absent in the purified complex. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis patterns of the three complexes were identical. Pyrolysis-mass spectrometry data correlated well with those obtained by the biochemical assays and suggested a low LPS content in the purified complex and a low polysaccharide content in the outer membrane complex. The purified complex was shown to be nonpyrogenic and could be prepared with the same yield as that of purified polysaccharide. The immunogenic activities of the complexes were studied in mice. The antibodies were measured by the enzyme-linked immunosorbent assay and the bactericidal antibody assay. All complexes induced immunoglobulin G antibodies to group C polysaccharide as well as to the serotype antigen, although the removal of polysaccharide and LPS resulted in a reduction of the immunogenic activities of outer membrane complex and purified complex, respectively. A second dose of all complexes produced a clear booster effect of both antibody responses. The antibodies were bactericidal.

EMTAGS:

Ultrastructure (0320); Infectious diseases (0310); Immunological factors (0136); Animal experiment (0112); Nonhuman (0777); Mouse (0727); Bacterium (0762)

DESCRIPTORS:

*neisseria meningitidis (0217472); *polysaccharide (0038281); *lipopolysaccharide (0027604); *antibody production (0002841); *vaccine (0051102)
electron microscopy (0015126); immunogenicity (0210042)

IDENTIFIERS: mouse

SECTION HEADINGS:

02602030000 IMMUNOLOGY AND SEROLOGY/ ANTIGENS/ Bacterial antigens
02624020000 /IMMUNITY TO INFECTIONS/ Immunity to bacteria
02603010000 /ANTIBODIES, IMMUNOGLOBULINS/ General
00402040000 MICROBIOLOGY/ SPECIAL BACTERIOLOGY/ *Neisseria*, *Veillonella*
00403030000 /IMMUNOLOGY AND SEROLOGY/ Toxins and antitoxins
00403040000 //Antigens and antibodies
00403080000 //Vaccines

15/5/58 (Item 1 from file: 76)
DIALOG(R)File 76:Life Sciences Collection
(c) 1995 Cambridge Sci Abs. All rts. reserv.

2007448 82003685595

Protein-dimeric polysaccharide conjugate vaccine
US Cl. 530/404; Int. Cl. C07K 17/02, 17/10; A61K 39/385, 39/116.
Marburg, S.; Tolman, R.L.
Merck & Co., Inc., Rahway, NJ (USA)

15/5/92 (Item 3 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 1996 Derwent Publ Ltd. All rts. reserv.

133095 DBA Accession No.: 92-05587 PATENT
New antigenic conjugate of HIV virus major neutralization determinant -
complex with Neisseria meningitidis outer membrane proteosome
application in AIDS, AIDS-related complex therapy; recombinant vaccine
PATENT ASSIGNEE: Merck-USA 1992
PATENT NUMBER: EP 471407 PATENT DATE: 920219 WPI ACCESSION NO.: 92-058471
(9208)
PRIORITY APPLIC. NO.: US 566638 APPLIC. DATE: 900813
NATIONAL APPLIC. NO.: EP 91202025 APPLIC. DATE: 910807
LANGUAGE: English

ABSTRACT: New amino acid sequences of an envelope fragment of HIV virus are disclosed, as well as immunological conjugates for use in AIDS and AIDS related complex (ARC) vaccines. The conjugates comprise HIV virus major neutralization determinant (PND) covalently linked, by a bienergetic spacer, to purified outer membrane proteosome (Omp) of Neisseria (preferably Neisseria meningitidis): (PND)n-(Omp), where n = the number of PND proteins covalently lined to Omp (1-50), PND may be formed of peptides of 5-35 amino acids containing the sequence Gly-X-Gly (X = Pro, Leu, Ala, Gln or Ser, preferably Pro). PND is prepared by expressing an artificial gene in Escherichia coli. Omp is isolated from N. meningitidis, N-acetylhomocystaminylated and reacted with N-omega-bromoacetylated PND. The conjugate may be formulated with virucide, immunostimulant, immunosuppressive, or anti-infective compounds, or with vaccines. An AIDS recombinant vaccine comprising the antigenic conjugate or cocktail of antigenic conjugates is specifically claimed for ARC or AIDS prevention. The conjugates are effective pre- or post-infection. (175pp)

DESCRIPTORS: HIV virus major neutralization determinant DNA sequence, RNA sequence, protein sequence, Neisseria meningitidis outer membrane proteosome conjugate prep., pot. AIDS, AIDS-related complex recombinant vaccine bacterium

SECTION: Pharmaceuticals-Vaccines; Microbiology-Genetics (D4,A1)

15/5/93 (Item 4 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 1996 Derwent Publ Ltd. All rts. reserv.

117946 DBA Accession No.: 91-05588 PATENT
Vaccine comprising antigen and separate complex as adjuvant - comprises phospholipid and/or sterol (not cholesterol) and solubilizing agent preferably glycoside, urea, guanidine, etc.
PATENT ASSIGNEE: Coopers-Anim.Health 1991
PATENT NUMBER: EP 415794 PATENT DATE: 910306 WPI ACCESSION NO.: 91-067322
(9110)
PRIORITY APPLIC. NO.: GB 8919819 APPLIC. DATE: 890901
NATIONAL APPLIC. NO.: EP 90309570 APPLIC. DATE: 900831
LANGUAGE: English

ABSTRACT: A vaccine for human or animal (preferably pig or sheep) comprises an antigen associated with a bacterium or mycoplasma and an iscom matrix (immune stimulating complex, IM), the antigen not being incorporated in the IM. Preferably, the IM comprises a phospholipid and a solubilizing agent, and optionally a sterol (not cholesterol). Vaccine production is also claimed. The antigen may be from Mycobacterium, Clostridium, Rickettsia, Spirochaete, Escherichia, Staphylococcus, Haemophilus, Bordetella, Vibrio, Salmonella, Streptococcus, Pasteurella, Legionella, Chlamydia, Pseudomonas, Actinobacillus, Campylobacter, Listeria and specified Mycoplasma spp., or the adherence factor in coli, prino protein or outer membrane proteins from Bordetella pertussis or Neisseria meningitidis. In the

ABSTRACT: Immunogenic, detoxified polysaccharide (PS) outer membrane protein (OMP) complex is prepared from bacterial OMP by successive centrifugal separation of OMP using, during various stages, TEEN buffer and (NH₄)₂SO₄, followed by dialysis against TEEN buffer. The dialyzed material is filtered and sterilized by filtration through a 0.22 um filter and the sterile OMP is coupled with sterile filtered PS. The combined product is precipitated using sterile, cold absolute EtOH and the precipitated complex obtained by centrifugation of the ethanol solution is washed free from any buffer product using absolute, sterile ethanol. The complex is dissolved in distilled water and stored at -20 deg. The complex is especially a lipopolysaccharide/OMP complex. The OMP is obtained from Gram-negative bacteria such as *Neisseria meningitidis* group B, *Neisseria gonorrhoeae*, *Escherichia coli*, *Haemophilus influenzae* type B and *Pseudomonas aeruginosa*. The product is useful as a vaccine for the treatment of infections caused by Gram-negative bacteria in animals, including humans. (19pp)

DESCRIPTORS: Gram-neg. bacterium, e.g. *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Escherichia coli*, *Haemophilus influenzae*, *Pseudomonas aeruginosa* detoxified polysaccharide-outer membrane protein complex prep., vaccine appl.

SECTION: Pharmaceuticals-Vaccines (D4)
?t s15/5/96-98

15/5/96 (Item 7 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 1996 Derwent Publ Ltd. All rts. reserv.

051624 DBA Accession No.: 86-09472 PATENT
Detoxified polysaccharide outer membrane protein complex - vaccine to protect animals against infections from bacteria from which the protein is derived

PATENT ASSIGNEE: U.S. Army 1986
PATENT NUMBER: US 6777068 PATENT DATE: 860401 WPI ACCESSION NO.:

86-176377 (8627)
PRIORITY APPLIC. NO.: US 777068 APPLIC. DATE: 850917
NATIONAL APPLIC. NO.: US 777068 APPLIC. DATE: 850917
LANGUAGE: English

ABSTRACT: Immunogenic detoxified polysaccharide outer membrane protein complexes are new and are used as vaccines to protect animals against infections by the bacteria from which they are derived. Suitable bacteria are Gram-negative bacteria such as *Neisseria meningitidis* group B, *Haemophilus influenzae* type b, *Neisseria gonorrhoea*, *Escherichia coli* and *Pseudomonas aeruginosa*. These complexes are prepared by suspending the outer membrane proteins in a buffer solution containing 1% zwitterionic detergent, 0.01 M EDTA, 0.05 M Tris-HCl and 0.15 M NaCl, pH 8. The suspension is stirred for 1 hr, sonicated and centrifuged and subjected to solid ammonium sulfate precipitation. After repeated precipitations and filtration the outer membranes are subjected to sterile filtering and then combined with the sterile filtered polysaccharide. In an example the outer membrane proteins of meningococcus cells of strain 44/76 were combined with capsular polysaccharide or detoxified lipopolysaccharide. (53 ref)

DESCRIPTORS: new vaccine prep., bacterium polysaccharide, outer membrane protein complex, *Pseudomonas aeruginosa*, *Neisseria gonorrhoea*, *Haemophilus influenzae*, *Escherichia coli*, *Neisseria meningitidis* bacterium

SECTION: Pharmaceuticals-Vaccines (D4)

15/5/97 (Item 8 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 1996 Derwent Publ Ltd. All rts. reserv.

016400 DBA Accession No.: 83-10380 PATENT
Immunogenic non-covalent polysaccharide-protein capsular complexes - *Haemophilus influenza* type b and *Neisseria meningitidis* group b; vaccine

Immune Responses in Mice to Different Noncovalent Complexes of
Meningococcal B Polysaccharide and Outer Membrane Proteins.
Lifely M R; Wang Z
Wellcome

Infect.Immun. 56, No. 12, 3221-27, 1988

CODEN: INFIBR ISSN: 0019-9567 LANGUAGE: English RECORD TYPE: Abstract

REPRINT ADDRESS: Department of Experimental Immunobiology, Wellcome
Biotech, Langley Court, Beckenham, Kent BR3 3BS, England.

ABSTRACT:

Non-covalent complexes of Neisseria meningitidis group B polysaccharide and outer membrane proteins (OMP) prepared by coextraction (WB-OMP) had a greater percentage bound B-polysaccharide, but a smaller lipopolysaccharide (LPS) content, were less heterogenous, and more efficient in immunizing mice than complexes prepared by separate extraction followed by mixing of the components (FB-OMP). Mice primed with a WB-OMP serotype 6 complex produced significantly higher titers of anti-B antibodies when immunized with homologous or heterologous serotype complexes than unprimed mice, and cross-reactions were shown to occur between OMP serotypes by immunoblotting. It is concluded that immunogenicity of B polysaccharide in mice is increased with increased binding to OMPs in non-covalent complexes.

SPECIAL FEATURES: 2 Fig. 5 Tab. 34 Ref.

LINK TERMS:

01; MENINGOCOCCAL-VACCINE --PH; I.P. --FT; MOUSE --FT; IN-VITRO --FT;
NEISSERIA --FT; MENINGITIDIS --FT; IMMUNE-RESPONSE --FT;
IMMUNIZATION --FT; POLYSACCHARIDE --FT; COMPLEX --FT; MEMBRANE --FT;
PROTEIN --FT; VACCINE --FT; INJECTION --FT; LAB.ANIMAL --FT; BACT. --FT;
GRAM-NEG. --FT; IMMUNITY --FT; SUBCELL.STRUCT. --FT; VACCINES --FT;
MENINGVAC --RN; PH --FT

SECTION HEADINGS: Immunological (20)

THEMATIC GROUPS: M (Microbiology)

15/5/116 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 1996 American Chemical Society. All rts. reserv.

119115323 CA: 119(11)115323a PATENT
Conjugates of the class II protein of the outer membrane of Neisseria meningitidis and of human immunodeficiency virus 1 (HIV-1)-related peptides
INVENTOR(AUTHOR): Emini, A.; Liu, Margaret A.; Marburg, Stephen; Tolman, Richard L.
LOCATION: USA
ASSIGNEE: Merck and Co., Inc.
PATENT: European Pat. Appl. ; EP 519554 A1 DATE: 921223
APPLICATION: EP 92201693 (920611) *US 715273 (910619)
PAGES: 66 pp. CODEN: EPXXDW LANGUAGE: English CLASS: C07K-017/06A;
C07K-003/28B; A61K-039/385B; A61K-039/21B DESIGNATED COUNTRIES: CH; DE; FR
; GB; IT; LI; NL
SECTION:
CA215002 Immunochemistry
CA234XXX Amino Acids, Peptides, and Proteins
IDENTIFIERS: Neisseria protein conjugate HIV virus peptide, major immunoenhancing protein Neisseria mitogen, vaccine human immunodeficiency virus
DESCRIPTORS:
Vaccines...
against human immunodeficiency virus, conjugates of Neisseria meningitidis major immunoenhancing protein with HIV principal neutralizing determinant peptide for
Neisseria meningitidis, group B...
major immunoenhancing protein from, conjugates with principal

15/5/118 (Item 7 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 1996 American Chemical Society. All rts. reserv.

119026229 CA: 119(3)26229g JOURNAL
Preparation, characterization, and immunogenicity of meningococcal
lipooligosaccharide-derived oligosaccharide-protein conjugates
AUTHOR(S): Gu, Xin Xing; Tsai, Chao Ming
LOCATION: Cent. Biol. Eval. Res., Fodd Drug Adm., Bethesda, MD, 20892,
USA
JOURNAL: Infect. Immun. DATE: 1993 VOLUME: 61 NUMBER: 5 PAGES:
1873-80 CODEN: INFIBR ISSN: 0019-9567 LANGUAGE: English
SECTION:
CA215002 Immunochemistry
IDENTIFIERS: immunogenicity Neisseria oligosaccharide protein conjugate
DESCRIPTORS:
Glycophospholipids, lipid A, monophosphates...
as adjuvant, with meningococcal oligosaccharide-protein complexes
Neisseria meningitidis...
oligosaccharide of, complexes of protein with, prepn. and
immunogenicity of
Immunoglobulins, G...
to meningococcal oligosaccharide-protein complexes
Mycolic acids...
trehalose diesters, as adjuvant, with meningococcal
oligosaccharide-protein complexes
Toxoids, tetanus, complexes...
with meningococcal oligosaccharide, prepn. and immunogenicity of
Oligosaccharides, complexes...
with protein, prepn. and immunogenicity of meningococcal
CAS REGISTRY NUMBERS:
1071-93-8 coupling by, of oligosaccharide to protein
99-20-7D diesters with mycolic acids, as adjuvant, with meningococcal
oligosaccharide-protein complexes

15/5/119 (Item 8 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 1996 American Chemical Society. All rts. reserv.

119007313 CA: 119(1)7313p PATENT
Culture of Neisseria meningitidis group B for manufacture of
polysaccharide-protein complex for vaccines
INVENTOR(AUTHOR): Basnakyan, Irina A.; Artemeva, Tamara A.; Aleksakhina,
Nina N.; Karabak, Vladimir I.; Borovkova, Valeriya M.; Kuvakina, Valentina
I.; Alliluev, Aleksandr P.; Kotelnikova, Olga V.; Valerius, Irina I.; et
al.
LOCATION: USSR
ASSIGNEE: Nii vaktsin syvorotok im.i.i.mechnikova; Mo nii epidemiologii
mikrobiologii im.g.n.gabrichhevskogo
PATENT: USSR ; SU 1750689 A1 DATE: 920730
APPLICATION: SU 4837952 (900517)
CODEN: URXXAF LANGUAGE: Russian CITATION: Izobreteniya 1992, (28), 37
CLASS: A61K-039/095A
SECTION:
CA216002 Fermentation and Bioindustrial Chemistry
CA215XXX Immunochemistry
IDENTIFIERS: Neisseria polysaccharide protein complex vaccine
DESCRIPTORS:
Alcohols, uses...
in extn. proteoglycans of Neisseria meningitidis group B for vaccines
Fermentation...
Neisseria meningitidis group B, for manuf. of proteoglycan for vaccines

115446-08-7P 115446-09-8P 115446-10-1P 115446-11-2P 115446-12-3P
 115446-13-4P 115446-14-5P 115446-15-6P 115446-16-7P 115466-43-8P
 of malaria circumsporozoites, prepn. and immunogenicity of, vaccine in
 relation to

Cell wall, outer membrane...
 of meningococcus, protein proteosomes of, lipopeptide complexes, as
 vaccine against malaria

Neisseria meningitidis...
 outer membrane protein proteosomes of, lipopeptide complexes, as
 vaccine against malaria

Malaria...
 vaccine against, proteosome-lipopeptide complexes in relation to

Lipopeptides, complexes...
 with proteosomes, as vaccine against malaria

CAS REGISTRY NUMBERS:
 115446-08-7P 115446-09-8P 115446-10-1P 115446-11-2P 115446-12-3P
 115446-13-4P 115446-14-5P 115446-15-6P 115446-16-7P 115466-43-8P
 of malaria circumsporozoites, prepn. and immunogenicity of, vaccine in
 relation to

15/5/133 (Item 22 from file: 399)
 DIALOG(R) File 399:CA SEARCH(R)
 (c) 1996 American Chemical Society. All rts. reserv.

96179171 CA: 96(21)179171p JOURNAL
 Enhancement of immunologic activity by noncovalent complexing of
 meningococcal group B polysaccharide and outer membrane proteins
 AUTHOR(S): Zollinger, Wendell D.; Mandrell, Robert E.; Griffiss, J.
 McLeod
 LOCATION: Walter Reed Army Inst. Res., Washington, DC, USA
 JOURNAL: Semin. Infect. Dis. DATE: 1982 VOLUME: 4, PAGES: 254-62
 CODEN: SEIDD8 ISSN: 0162-5454 LANGUAGE: English
 SECTION:

CA115002 Immunochemistry
 IDENTIFIERS: Meningococcus polysaccharide protein complex vaccine
 DESCRIPTORS:

Vaccines...
 meningococcal group B polysaccharide complex with outer membrane
 protein as

Polysaccharides, biological studies...
 of meningococcal group B, complex with outer membrane protein as
 vaccine

Proteins...
 of meningococcal outer membrane, complex with polysaccharide as vaccine

Neisseria meningitidis, group B...
 polysaccharide of, complex with outer membrane proteins, as vaccine

Cell wall, outer membrane...
 protein of, meningococcal, complex with polysaccharide as vaccine

?display sets

Set	Items	Description
S1	35583	CHONDROITIN?
S2	29408	S1 NOT PY>1992
S3	1	S2(20N)EDWARDSIELL?
S4	9599	EDWARDSIELL?
S5	9	S4(20N)(ATTENUAT? OR AVIRULEN?)
S6	5	RD S5 (unique items)
S7	543	EDWARDSIELL?(4W)ICTALUR?
S8	3	S7(10N)(AVIRULEN? OR ATTENUAT? OR NON(2W)PATHOG?)
S9	21122	NEISSERIA?(2W)MENING?

S10	0	S9(20N)NONCOVALENT?
S11	19969	S9 NOT PY>1994
S12	0	S11(20N)(ESHERICHIA?)
S13	2835	S11(10N)(OUTER?(4W)MEMBRAN? OR PROTEIN?)
S14	333	S13(10N)COMPLEX?
S15	152	RD S14 (unique items)
S16	2	S15(20N)NONCOVALEN?
?		

Neisseria meningitidis group B, proteoglycan manuf. for
Proteoglycans, preparation...

of Neisseria meningitidis group B, prepn. and isolation for vaccines of
Neisseria meningitidis, group B...

polysaccharide protein complex for vaccines of, manuf. and prepn. of
?t s15/5/120,128,133

15/5/120 (Item 9 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 1996 American Chemical Society. All rts. reserv.

118145540 CA: 118(15)145540r JOURNAL

Meningococcal lipopolysaccharide (LPS)-derived oligosaccharide-protein
conjugates evoke outer membrane protein- but not LPS-specific bactericidal
antibodies in mice: Influence of adjuvants

AUTHOR(S): Verheul, A. F. M.; Van Gaans, J. A. M.; Wiertz, E. J. H.;
Snippe, H.; Verhoef, J.; Poolman, J. T.

LOCATION: Eijkman-Winkler Lab. Med. Microbiol., Exp. Med. Microbiol.,
Utrecht Univ., 3584 CX, Utrecht, Neth.

JOURNAL: Infect. Immun. DATE: 1993 VOLUME: 61 NUMBER: 1 PAGES: 187-96

CODEN: INFIBR ISSN: 0019-9567 LANGUAGE: English

SECTION:

CA215003 Immunochemistry

IDENTIFIERS: Neisseria oligosaccharide protein conjugate antibody
adjuvant

DESCRIPTORS:

Immunoglobulins, G2a... Immunoglobulins, G2b...

bactericidal, to outer membrane protein-oligosaccharide complexes of
meningococcus, adjuvants effect on

Vaccines...

meningococcal outer membrane protein-oligosaccharide complexes as,
adjuvants effect on

Proteins, specific or class...

OMP (outer membrane protein), complexes, with oligosaccharides,
meningococcal, bactericidal antibodies to protein portion of, adjuvants
effect on

Neisseria meningitidis, group B...

outer membrane protein-oligosaccharide complexes of, as vaccines,
adjuvants effect on

Oligosaccharides, complexes...

with outer membrane proteins, bactericidal antibodies to protein
portion of, adjuvants effect on

CAS REGISTRY NUMBERS:

66594-14-7 106392-12-5 adjuvant, bactericidal antibodies formation to
meningococcal outer-membrane protein-oligosaccharide complexes response
to

15/5/128 (Item 17 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 1996 American Chemical Society. All rts. reserv.

109052803 CA: 109(7)52803c JOURNAL

Proteosome-lipopeptide vaccines: enhancement of immunogenicity for
malaria CS peptides

AUTHOR(S): Lowell, George H.; Ballou, W. Ripley; Smith, Lynette F.;
Wirtz, Robert A.; Zollinger, Wendell D.; Hockmeyer, Wayne T.

LOCATION: Dep. Bac. Dis., Walter Reed Army Inst., Washington, DC,
20307-5100, USA

JOURNAL: Science (Washington, D. C., 1883-) DATE: 1988 VOLUME: 240

NUMBER: 4853 PAGES: 800-2 CODEN: SCIEAS ISSN: 0036-8075 LANGUAGE:
English

SECTION:

CA215002 Immunochemistry

CA263XXX Pharmaceuticals

neutralizing determinant peptides of human immunodeficiency virus, for vaccine

Mitogens...

major immunoenhancing protein from *Neisseria meningitidis* activity as Proteins, specific or class, OMP-MC (outer membrane protein-macromol. complex)...

major immunoenhancing protein from, of *Neisseria meningitidis*, conjugates with principal neutralizing determinant peptides of human immunodeficiency virus, for vaccine

Escherichia coli... *Saccharomyces cerevisiae*...

major immunoenhancing protein of *Neisseria meningitidis* recombinant prodn. in

Proteins, specific or class...

MIEP (major immunoenhancing protein), of *Neisseria meningitidis*, conjugates with human immunodeficiency virus principal neutralizing determinant peptide, for vaccine

Fermentation...

of *Neisseria meningitidis* B11, for major immunoenhancing protein prepn. for conjugation with human immunodeficiency virus principal neutralizing determinant peptides

Peptides, conjugates, compounds...

of principal neutralizing determinant of human immunodeficiency virus, with major immunoenhancing protein of *Neisseria meningitidis*, for vaccine

Plasmid and Episome...

pGall10/p/pCI/MIEP, DNA for major immunoenhancing protein of *Neisseria meningitidis* on

Virus, animal, human immunodeficiency...

principal neutralizing determinant peptides derived from, conjugates with major immunoenhancing protein of *Neisseria meningitidis*, for vaccine

CAS REGISTRY NUMBERS:

7423-55-4 anhydride formation from

121696-42-2D 122576-51-6D 122589-16-6D 122589-17-7D 122589-18-8D
 122589-19-9D 122589-20-2D 122589-21-3D 122589-22-4D 130099-37-5D
 131473-70-6D 141032-15-7D 141032-22-6D 141032-26-0D 141873-05-4D
 141873-06-5D 141873-07-6D 141873-08-7D 141873-09-8D 141873-10-1D
 141873-24-7D 141873-25-8D 141873-26-9D 141873-27-0D 141873-29-2D
 141887-55-0D 141887-56-1D 141887-57-2D 147863-16-9D 147894-66-4D
 147894-67-5D major immunoenhancing protein conjugates, for vaccine against human immunodeficiency virus

141032-25-9P prepn. and cyclization of, in prepn. of vaccine against human immunodeficiency virus

141053-45-4P prepn. and reaction of, for conjugate prepn. for vaccine against human immunodeficiency virus

141032-17-9P 141032-19-1P prepn. and reaction of, in principal neutralizing determinant peptide of human immunodeficiency virus prepn.

141032-27-1P prepn. and reaction with principal neutralizing determinant peptide of human immunodeficiency virus of

141032-14-6P 141032-15-7P 141032-21-5P 141032-22-6P 141032-24-8P
 141032-26-0P prepn. of, for conjugate prepn. for vaccine against human immunodeficiency virus

35661-39-3P 39608-30-5P 71989-23-6P 71989-31-6P 83792-47-6P
 84624-27-1P 86060-93-7P 86060-98-2P 109053-20-5P 109425-51-6P
 115520-21-3P 119767-84-9P 130397-19-2P 142717-04-2P reaction of, in principal neutralizing determinant peptide of human immunodeficiency virus prepn.

147863-17-0 148528-64-7 reaction of, with maleimidopropionic acid hydroxysuccinimide ester

55750-62-4 reaction of, with principal neutralizing determinant peptide trifluoroacetate salt derived from human immunodeficiency virus

141053-45-4DP resin-bound, prepn. and reaction of, for conjugate prepn. for vaccine against human immunodeficiency virus

141032-16-8DP resin-bound, prepn. and reaction of, in principal neutralizing determinant peptide of human immunodeficiency virus prepn.

35661-40-6DP 103213-32-7DP resin-bound, reaction of, in principal

preparation
PATENT ASSIGNEE: SK+F-RIT 1983
PATENT NUMBER: EP 88303 PATENT DATE: 830914 WPI ACCESSION NO.: 83-766164
(8338)
PRIORITY APPLIC. NO.: US 354878 APPLIC. DATE: 820304
NATIONAL APPLIC. NO.: EP 83101843 APPLIC. DATE: 830225
LANGUAGE: French

ABSTRACT: A process is described for the preparation of immunogenic non-covalent, polysaccharide-protein bacterial capsular complexes, free from lipopolysaccharides, from an aqueous suspension of bacteria. It comprises inactivating the bacteria by addition of a quaternary ammonium salt (preferably cetrimonium bromide), immediately recovering the insoluble fraction, which is taken up in a 0.2-2N non-toxic alkali-metal or alkaline-earth metal salt solution. Contaminants are precipitated out by addition of 25% aqueous ethanol, removing the quaternary ammonium salt by addition of a water-soluble benzoate, sulfocyanide or iodide and separating the precipitate to give an aqueous solution from which the complex is recovered. The complex is purified by ultrafiltration and lyophilization. Haemophilus influenzae type b and Neisseria meningitidis group b were used. The method is used for the preparation of vaccines against meningitis using effective doses of the above complexes. (38 ref)

DESCRIPTORS: Haemophilus influenza type b, Neisseria meningitidis polysaccharide protein capsular complex prep., meningitis vaccine prep.
SECTION: Pharmaceuticals-Vaccines; Purification-Downstream Processing (D4, L1)

15/5/98 (Item 9 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 1996 Derwent Publ Ltd. All rts. reserv.

013061 DBA Accession No.: 83-05773

Monoclonal antibodies to Neisseria meningitidis - hybridoma construction and monoclonal antibody production and characterization (conference abstract)

AUTHOR: Larose Y; +Brodeur B R; Ashton F E; Ryan A; Diena B B
CORPORATE SOURCE: Bureau of Microbiology, Laboratory Centre for Disease Control, Ottawa, Ontario K1A D12, Canada.
JOURNAL: Abstr.Can.Soc.Microbiol. (32 Meet., 92) 1982
CODEN: 0006T

LANGUAGE: English

ABSTRACT: Somatic cell fusion was used to produce monoclonal antibody (MnAb) to outer membrane proteins (MOMP's) of two different strains of Neisseria meningitidis serogroup B, serotype 2. Balb/C mice were immunized with outer membrane complex (OMC) and immune spleen cells were fused with a nonsecreting myeloma cell line SP2/O to form hybridoma cell lines. Short term (6 days) i.v. administration of OMC produced IgM antibodies and long term i.p. injections produced MnAb from all subclasses of IgG. The hybrids were tested for antibody production by ELISA using as coating antigens OMC from five disease-associated strains of N.meningitidis, having five distinct MOMP profiles as judged by sodium dodecyl sulfate polyacrylamide gel with serotype 2b strains while MnAb to the 43-46K MOMP's reacted with some serotype 2a, 2b, 2c and nontypable strains. Certain MnAb were bactericidal in nature. (0 ref)

DESCRIPTORS: hybridoma construction, monoclonal antibody prep., Neisseria meningitidis outer membrane protein

SECTION: Cell Culture-Animal Cell Culture; Pharmaceuticals-Vaccines (J1,D4)

?t s15/5/109,116,118,119

15/5/109 (Item 10 from file: 377)
DIALOG(R)File 377:Derwent Drug File
(c) 1996 Derwent Info Ltd. All rts. reserv.

immunogenic complex the antigen may also be from fungi, protozoa, helminths, viruses, etc. More specifically, the solubilizing agent may be e.g. surfactant, urea or guanidine. Phospholipids include phosphatidylcholine and phosphatidylethanolamine. Glycosides are preferably saponins, especially Quil A. Sterols include lanosterol, lumisterol, stigmasterol and sitosterol. (13pp)
DESCRIPTORS: human, pig, sheep vaccine prep., act. against Mycobacterium, Clostridium, Rickettsia, Spirochaete, Escherichia, Staphylococcus, Haemophilus, Bordetella, Vibrio, Salmonella, Streptococcus, Pasteurella, Legionella, Chlamydia, Pseudomonas, Actinobacillus, Campylobacter, Listeria, Mycoplasma spp., antigen with iscom matrix forming immunogen complex fungus protozoon helminth virus mammal bacterium immune stimulating complex
SECTION: Pharmaceuticals-Vaccines (D4)

15/5/94 (Item 5 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 1996 Derwent Publ Ltd. All rts. reserv.

086504 DBA Accession No.: 89-04495 PATENT
New vaccine against group B Neisseria meningitidis - hyperimmune gamma-globulin for meningitidis therapy
PATENT ASSIGNEE: Centro-Nac.Biopreparados 1989
PATENT NUMBER: EP 301992 PATENT DATE: 890201 WPI ACCESSION NO.: 89-033857 (8905)
PRIORITY APPLIC. NO.: CU 8712587 APPLIC. DATE: 870730
NATIONAL APPLIC. NO.: EP 88500077 APPLIC. DATE: 880730
LANGUAGE: English
ABSTRACT: A new vaccine with wide long-lasting protective range against different pathogenic serotypes of group B Neisseria meningitidis contains an immunologically effective quantity of the protein antigenic complex of 65,000-95,000 mol.wt. The vaccine confers antigenic immunity in the presence of different known pathogenic serotypes and induces formation of bactericidal antibodies. Also new is antimeningococcic hyperimmune gamma-globulin for the treatment of meningitidis and meningococemia caused by any of the various pathogenic serotypes of group B N. meningitidis. A new specific transfer factor (dialysable factor from leukocyte extract) can be used to transfer T-lymphocyte immunity against group B N. meningitidis. The new vaccine is obtained starting from live microorganisms of any of the pathogenic serotypes of the B group. The outer membrane vesicles and the protein antigenic complex are extracted using detergent, enzyme and ultrasound. After removal of the nucleic acids, the product is purified by a dissociating treatment and column chromatography. The hyperimmune gamma-globulin and the transfer factor are obtained from the serum of vaccinated adults. (12pp)

DESCRIPTORS: new vaccine against group-B Neisseria meningitidis, hyperimmune gamma-globulin, appl. in meningitidis therapy bacterium
SECTION: Pharmaceuticals-Vaccines; Pharmaceuticals-Other (D4,D5)

15/5/95 (Item 6 from file: 357)
DIALOG(R)File 357:Derwent Biotechnology Abs
(c) 1996 Derwent Publ Ltd. All rts. reserv.

071426 DBA Accession No.: 88-01774 PATENT
Process for the preparation of detoxified polysaccharide-outer membrane proteins - from bacterial envelopes, and their use as vaccines (US Equivalent)
PATENT ASSIGNEE: U.S.Army 1987
PATENT NUMBER: US 4707543 PATENT DATE: 871117 WPI ACCESSION NO.: 86-176377 (8627)
PRIORITY APPLIC. NO.: US 777068 APPLIC. DATE: 850917
NATIONAL APPLIC. NO.: US 777068 APPLIC. DATE: 850917
LANGUAGE: English

Patent No.: US Patent 5,371,197

Language: English

Document Type: Patent

Subfile: 33 Medical and Pharmaceutical Biotechnology Abstracts; 01

Microbiology Abstracts A Industrial and Applied Microbiology

A covalent protein-dimeric polysaccharide conjugate immunogen wherein: a first polysaccharide is covalently bound to a protein; a second polysaccharide is covalently bound to the first polysaccharide; the first and second polysaccharides are derived from one or two different species of pathogenic bacteria; the protein is the outer membrane protein complex derived from *Neisseria meningitidis* b, which enhances the immunogenicity of the polysaccharides to which it is covalently conjugated; and *meningitidis* b, which enhances the immunogenicity of the polysaccharides to which it is covalently conjugated; and the polysaccharides are derived from the group of bacteria selected from *Haemophilus influenzae* b, *Streptococcus pneumoniae* subtype 1, 2, 3, 4, 5, 6 A, 6 B, 7 F, 8, 9 N, 9 V, 10 A, 11 A, 12 F, 14, 15 B, 17 F, 18 C, 19 A, 19 F, 20, 22 F, 23 F, 33 F.

Descriptors: patents; vaccines; patents; vaccines

Section Heading Codes: 33050; 01099

15/5/70 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 1996 Knight-Ridder Info. All rts. reserv.

07753707 91272707

[The sorption of a protein-polysaccharide complex isolated from *Neisseria meningitidis* serogroup B on aluminum hydroxide gels and the immunological activity of the sorbed preparations]

Sorbtsiia belkovo-polisakharidnogo kompleksa, vydelenno iz *Neisseria meningitidis* serogruppy B, na geli gidroksida aliuminiia i immunologicheskaiia aktivnost' sorbirovannykh preparatov.

Bugaev LV; Vartanian IuP; Karabak VI; Kil'diushevskaiia TV; Kuvakina VI; Basnak'ian IA; Alliluev AP; Machul'skaiia KV; Borovkova VM; Petrov AB

Zh Mikrobiol Epidemiol Immunobiol (USSR) Nov 1990, (11) p50-6, ISSN 0372-9311 Journal Code: Y90

Languages: RUSSIAN Summary Languages: ENGLISH

Document type: JOURNAL ARTICLE English Abstract

JOURNAL ANNOUNCEMENT: 9109

Subfile: INDEX MEDICUS

The protein-polysaccharide complex, isolated from group B *N. meningitidis*, is a variant of vaccine for the prophylaxis of group B *N. meningitidis* infection. In this investigation the influence of the complex of the physical properties of aluminium hydroxide gels, the amount of gel, pH and the duration of sorption on the process of sorption has been studied. Aluminium hydroxide has been shown to produce a stimulating effect on the response of mice to the polysaccharide and protein contained in the complex after immunization made in two injections. Gels with a smaller particle size have been found to possess greater adjuvant activity, as well as greater absorbing activity. The immunological activity of the complex, adsorbed ex tempore, has proved to be no different from that of the complex adsorbed in an hour.

Tags: Animal

Descriptors: *Bacterial Proteins--Isolation and Purification--IP; *Lipopolysaccharides--Isolation and Purification--IP; **Neisseria meningitidis*; Aluminum Hydroxide; Antibodies, Bacterial--Blood--BL; Bacterial Proteins--Immunology--IM; Bacterial Vaccines--Immunology--IM; Bacterial Vaccines--Isolation and Purification--IP; Chemistry, Physical; Gels; Hydrogen-Ion Concentration; Immunization; Immunosorbent Techniques; Lipopolysaccharides--Immunology--IM; Mice; Mice, Inbred CBA; *Neisseria meningitidis*--Classification--CL; *Neisseria meningitidis*--Immunology--IM; Particle Size; Serotyping; Time Factors

CAS Registry No.: 0 (Antibodies, Bacterial); 0 (Bacterial Proteins); 0 (Bacterial Vaccines); 0 (Gels); 0 (Lipopolysaccharides); 21645-51-2 (Aluminum Hydroxide)

*10066 Biochemical Studies-Lipids
 *10068 Biochemical Studies-Carbohydrates
 *10508 Biophysics-Membrane Phenomena
 *22018 Pharmacology-Immunological Processes and Allergy
 *31000 Physiology and Biochemistry of Bacteria
 *34504 Immunology and Immunochemistry-Bacterial, Viral and Fungal
 *36002 Medical and Clinical Microbiology-Bacteriology
 01058 Microscopy Techniques-Electron Microscopy
 10010 Comparative Biochemistry, General
 10054 Biochemical Methods-Proteins, Peptides and Amino Acids
 10056 Biochemical Methods-Lipids
 10058 Biochemical Methods-Carbohydrates
 10504 Biophysics-General Biophysical Techniques
 10804 Enzymes-Methods
 12100 Movement (1971-)
 13004 Metabolism-Carbohydrates
 13012 Metabolism-Proteins, Peptides and Amino Acids
 15002 Blood, Blood-Forming Organs and Body Fluids-Blood and Lymph
 Studies
 23006 Temperature: Its Measurement, Effects and
 Regulation-Hypothermia, Hyperthermia
 23007 Temperature: Its Measurement, Effects and
 Regulation-Thermopathology (1971-)
 30500 Morphology and Cytology of Bacteria
 32300 Microbiological Ultrastructure (1972-)
 34502 Immunology and Immunochemistry-General; Methods
 36001 Medical and Clinical Microbiology-General; Methods and
 Techniques

Biosystematic Codes:

05110 Neisseriaceae (1979-)
 86375 Muridae

Super Taxa:

Microorganisms; Bacteria; Animals; Chordates; Vertebrates; Nonhuman
 Vertebrates; Mammals; Nonhuman Mammals; Rodents

15/5/49 (Item 49 from file: 5)
 DIALOG(R)File 5:BIOSIS PREVIEWS(R)
 (c) 1996 BIOSIS. All rts. reserv.

995727 BIOSIS Number: 09030666

CHARACTERIZATION OF A NATIVE PROTEIN LIPO POLY SACCHARIDE LIPID COMPLEX
 FROM NEISSERIA-MENINGITIDIS

ZOLLINGER W D; KASPER D L

ABSTR ANNU MEET AM SOC MICROBIOL 72. 1972 89 CODEN: ASMAC

Full Journal Title: Abstracts of the Annual Meeting of the American
 Society for Microbiology

Document Type: CONFERENCE PAPER

Descriptors/Keywords: ABSTRACT RABBIT IMMUNOGENIC CELL WALL

Concept Codes:

*10064 Biochemical Studies-Proteins, Peptides and Amino Acids
 *10066 Biochemical Studies-Lipids
 *10068 Biochemical Studies-Carbohydrates
 *10506 Biophysics-Molecular Properties and Macromolecules
 *31000 Physiology and Biochemistry of Bacteria
 *34504 Immunology and Immunochemistry-Bacterial, Viral and Fungal
 *34508 Immunology and Immunochemistry-Immunopathology, Tissue
 Immunology
 30500 Morphology and Cytology of Bacteria

Biosystematic Codes:

07200 Eubacteriales (1969-78)
 86040 Leporidae

Super Taxa:

Microorganisms; Bacteria; Animals; Chordates; Vertebrates; Nonhuman
 Vertebrates; Mammals; Nonhuman Mammals; Lagomorphs

33304 Virology-Bacteriophage
34502 Immunology and Immunochemistry-General; Methods
34504 Immunology and Immunochemistry-Bacterial, Viral and Fungal
Biosystematic Codes:
04810 Enterobacteriaceae (1979-)
05110 Neisseriaceae (1979-)
Super Taxa:
Microorganisms; Bacteria

15/5/43 (Item 43 from file: 5)
DIALOG(R)File 5:BIOSIS PREVIEWS(R)
(c) 1996 BIOSIS. All rts. reserv.

5814312 BIOSIS Number: 83076619
LEUKOCYTE ELASTASE ACTIVITY IN MENINGOCOCCAL SEPTICEMIA ASSOCIATED
COAGULOPATHY
CANAVAN D; ROBINSON F; TURKINGTON P
THE UNIV. KUWAIT, FAC. ALLIED HEALTH SCI., PO BOX 31470, 90805
SULAIBIKHAT, KUWAIT.
J CLIN PATHOL (LOND) 39 (12). 1986 (RECD. 1987). 1304-1305. CODEN:
JCPAA

Full Journal Title: Journal of Clinical Pathology (London)
Language: ENGLISH
The concentration of the elastase-.alpha.1 proteinase inhibitor complex
(E-.alpha.1 PI) in a meningococcal infection in an index case with severe
changes in haemostatis was measured. The concentration of the E-.alpha.1 PI
complex was increased throughout the duration of the illness, although
concentrations of the blood clotting factors were severely decreased. The
release of polymorphonuclear elastase activity may contribute to the
depletion in clotting factors.
Descriptors/Keywords: HUMAN NEISSERIA-MENINGITIDIS CLOTTING FACTOR
HEMOSTASIS ELASTASE-ALPHA-1-PROTEINASE INHIBITOR COMPLEX

Concept Codes:
*10808 Enzymes-Physiological Studies
*15002 Blood, Blood-Forming Organs and Body Fluids-Blood and Lymph
Studies
*15004 Blood, Blood-Forming Organs and Body Fluids-Blood Cell Studies
*15006 Blood, Blood-Forming Organs and Body Fluids-Blood, Lymphatic and
Reticuloendothelial Pathologies
*15008 Blood, Blood-Forming Organs and Body Fluids-Lymphatic Tissue and
Reticuloendothelial System
*36002 Medical and Clinical Microbiology-Bacteriology
02508 Cytology and Cytochemistry-Human
10064 Biochemical Studies-Proteins, Peptides and Amino Acids

Biosystematic Codes:
05110 Neisseriaceae (1979-)
86215 Hominidae

Super Taxa:
Microorganisms; Bacteria; Animals; Chordates; Vertebrates; Mammals;
Primates; Humans

15/5/46 (Item 46 from file: 5)
DIALOG(R)File 5:BIOSIS PREVIEWS(R)
(c) 1996 BIOSIS. All rts. reserv.

4853111 BIOSIS Number: 79095426
IMMUNITY AND PROTECTION OF MICE AGAINST NEISSERIA-MENINGITIDIS GROUP B BY
VACCINATION USING POLYSACCHARIDE COMPLEXED WITH OUTER MEMBRANE PROTEINS A
COMPARISON WITH PURIFIED B POLYSACCHARIDE
MORENO C; LIFELY M R; ESDAILE J
DEP. EXP. IMMUNOBIOLOG., WELLCOME RES. LAB., BECKENHAM, KENT BR3 3BS, UK.
INFECT IMMUN 47 (2). 1985. 527-533. CODEN: INFIB
Full Journal Title: Infection and Immunity
Language: ENGLISH

Completed processing all files

2835 S13

3024887 COMPLEX?

S14 333 S13(10N)COMPLEX?

?rd s14

>>>Duplicate detection is not supported for File 125.

>>>Duplicate detection is not supported for File 337.

>>>Duplicate detection is not supported for File 340.

>>>Duplicate detection is not supported for File 348.

>>>Duplicate detection is not supported for File 350.

3,11,29,36

15/5/3 (Item 3 from file: 5)

DIALOG(R)File 5:BIOSIS PREVIEWS(R)

(c) 1996 BIOSIS. All rts. reserv.

11143920 BIOSIS Number: 97343920

Escherichia coli J5 LPS as non-covalent complex vaccine with Neisseria meningitidis group B outer membrane protein produces protective antibodies against gram-negative bacteremia

Bhattacharjee A; Taylor R; Collins H; Opal S; Cross A; Zollinger W; Sadoff J

Walter Reed Army Inst. Res., Washington, DC, USA

Abstracts of the General Meeting of the American Society for Microbiology 94 (0). 1994. 151.

Full Journal Title: 94th General Meeting of the American Society for Microbiology, Las Vegas, Nevada, USA, May 23-27, 1994. Abstracts of the General Meeting of the American Society for Microbiology

ISSN: 1060-2011

Language: ENGLISH

Document Type: CONFERENCE PAPER

Print Number: Biological Abstracts/RRM Vol. 046 Iss. 008 Ref. 121638

Descriptors/Keywords: MEETING ABSTRACT; ESCHERICHIA COLI; NEISSERIA MENINGITIDIS; PSEUDOMONAS AERUGINOSA; RABBIT; NEUTROPENIC RAT; PASSIVE IMMUNIZATION

Concept Codes:

*15006 Blood, Blood-Forming Organs and Body Fluids-Blood, Lymphatic and Reticuloendothelial Pathologies

*22018 Pharmacology-Immunological Processes and Allergy

*34504 Immunology and Immunochemistry-Bacterial, Viral and Fungal

*34508 Immunology and Immunochemistry-Immunopathology, Tissue Immunology

*36002 Medical and Clinical Microbiology-Bacteriology

00520 General Biology-Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals

10064 Biochemical Studies-Proteins, Peptides and Amino Acids

10506 Biophysics-Molecular Properties and Macromolecules

15004 Blood, Blood-Forming Organs and Body Fluids-Blood Cell Studies

15008 Blood, Blood-Forming Organs and Body Fluids-Lymphatic Tissue and Reticuloendothelial System

30500 Morphology and Cytology of Bacteria

31000 Physiology and Biochemistry of Bacteria

Biosystematic Codes:

06507 Neisseriaceae (1992-)

06508 Pseudomonadaceae (1992-)

06702 Enterobacteriaceae (1992-)

86040 Leporidae

86375 Muridae

Super Taxa:

Microorganisms; Bacteria; Eubacteria; Animals; Chordates; Vertebrates; Nonhuman Vertebrates; Mammals; Nonhuman Mammals; Lagomorphs; Rodents

15/5/11 (Item 11 from file: 5)

DIALOG(R)File 5:BIOSIS PREVIEWS(R)

(c) 1996 BIOSIS. All rts. reserv.

8152253 BIOSIS Number: 91073253

IMMUNOGENICITY IN ADULT MALES OF A NEISSERIA-MENINGITIDIS GROUP B VACCINE
COMPOSED OF POLYSACCHARIDE COMPLEXES WITH OUTER MEMBRANE PROTEINS

LIFELY M R; ROBERTS S C; SHEPHERD W M; ESDAILE J; WANG Z; CLEVERLY A;
AULAQI A A; MORENO C

DEP. EXP. IMMUNOBIOLOG., WELLCOME BIOTECH, WELLCOME FOUND. LTD., LANGLEY
COURT, BECKENHAM, KENT BR3 3BS.

VACCINE 9 (1). 1991. 60-66. CODEN: VACCD

Full Journal Title: Vaccine

Language: ENGLISH

Twenty five adult male volunteers were given a vaccine composed of the capsular B polysaccharide non-covalently complexed to serotype 6 outer membrane proteins (OMP) of *Neisseria meningitidis*. Subjects were divided into three dose groups receiving 50, 100 or 150 .mu.g vaccine in aluminium hydroxide in each of three injections spaced 4 weeks apart. Systemic signs/symptoms considered clinically significant were recorded on 6% (4/70) of occasions and were succeeded by withdrawal of two volunteers from the study. Local injection site reactions, mostly mild to moderate, were reported after all vaccinations with one such reaction leading to a third volunteer withdrawing from the study. Geometric mean anti-B responses before immunization and 1 week after the third immunization (9 weeks) were 3.60 and 7.12 .mu.g ml⁻¹ in the 50 .mu.g group ($p < 0.05$), 2.05 and 12.19 .mu.g ml⁻¹ in the 100 .mu.g group ($p < 0.001$) and 3.68 and 14.20 .mu.g ml⁻¹ in the 150 .mu.g group ($p < 0.001$). The anti-B response was predominantly of the IgM isotype and persistence above prevaccination levels was evident for at least 12 months. Anti-type 6 OMP responses were also evidenced with geometric mean multiplication increases over prevaccination levels at 9 weeks and 6 months of 7.8 and 4.2 for the 50 .mu.g group, 11.6 and 5.6 for the 100 .mu.g group and 6.8 and 3.4 for the 150 .mu.g group. The bulk of this response was of the IgG isotype. Passive protection of mice was achieved with both pre- and post-vaccination (9 weeks; 100 and 150 .mu.g groups) pools of sera. Protection was abolished by prior adsorption of sera with B polysaccharide.

Descriptors/Keywords: HUMAN.

Concept Codes:

*22005 Pharmacology-Clinical Pharmacology (1972-)
*22018 Pharmacology-Immunological Processes and Allergy
*34504 Immunology and Immunochemistry-Bacterial, Viral and Fungal
*36002 Medical and Clinical Microbiology-Bacteriology
10064 Biochemical Studies-Proteins, Peptides and Amino Acids
10068 Biochemical Studies-Carbohydrates
12512 Pathology, General and Miscellaneous-Therapy (1971-)
31000 Physiology and Biochemistry of Bacteria

Biosystematic Codes:

05110 Neisseriaceae (1979-)
86215 Hominidae

Super Taxa:

Microorganisms; Bacteria; Animals; Chordates; Vertebrates; Mammals;
Primates; Humans

15/5/36 (Item 36 from file: 5)

DIALOG(R)File 5:BIOSIS PREVIEWS(R)

(c) 1996 BIOSIS. All rts. reserv.

7295925 BIOSIS Number: 38076446

CAPSULAR POLYSACCHARIDES AS VACCINE CANDIDATES

JENNINGS H J

DIV. BIOL. SCI., NATL. RES. COUNCIL, OTTAWA, ONTARIO, CANADA K1A 0R6.

JANN, D. AND B. JANN (ED.). CURRENT TOPICS IN MICROBIOLOGY AND
IMMUNOLOGY, VOL. 150. BACTERIAL CAPSULES. IX+162P. SPRINGER-VERLAG: BERLIN,
WEST GERMANY; NEW YORK, NEW YORK, USA. ILLUS. ISBN 3-540-51049-4; ISBN
0-387-51049-4. 0 (0). 1990. 97-128. CODEN: CTMIA

Language: ENGLISH

Descriptors/Keywords: REVIEW STREPTOCOCCUS-PNEUMONIAE

study for a drug, one of the objectives is to investigate a possible causal relationship between the suspect drug and a specific adverse reaction. In that context, two causality assessment problems arise: the Retrodictive one, where each of the adverse events reported is considered separately in order to determine whether the suspect drug was the cause for each of the cases, and the Predictive one, which is the topic of this thesis, where an overall measure of the propensity of the suspect drug causing the adverse event in question is established. Four Bayesian procedures for deriving the predictive distribution of the causal status (drug vs. non-drug) for the next drug user are introduced, differing mainly in the data scheme available. The different data schemes considered, differ with respect to whether the causal agent of the adverse event is assumed known or a subjective probabilistic (retrodictive) assessment for the cause of each adverse event is provided or, simply, making use of the complex nature of the information that appear in all adverse event reports. All procedures are applied to a study linking Mexiletine (an antiarrhythmic drug) therapy with neutropenia (a disease in the blood associated with a mortality rate of about 30%).

23/5/7 (Item 7 from file: 35)
DIALOG(R)File 35:Dissertation Abstracts Online
(c) 1997 UMI. All rts. reserv.

0975758 ORDER NO: AAD87-28912
PHARMACODYNAMIC MODELING OF ANTIMICROBIAL ACTIVITY: PIPERACILLIN
VERSUS PSEUDOMONAS AERUGINOSA

Author: ZHI, JIANGUO

Degree: PH.D

Year: 1987

Corporate Source/Institution: THE UNIVERSITY OF CONNECTICUT
(0056) Source: VOLUME 48/10-B OF DISSERTATION ABSTRACTS
INTERNATIONAL. PAGE 2941. 135 PAGES

Descriptors: HEALTH SCIENCES, PHARMACY

Descriptor Codes: 0572

A pharmacodynamic model describing the interaction of antibiotics with bacteria was developed. Two possible interactions of piperacillin with *Pseudomonas aeruginosa* (ATCC 28753) were tested in vitro in Mueller-Hinton broth at 37°C and in vivo in a mouse systemic infection model. Clinically relevant dosage regimens such as single bolus dosing, multiple doses and constant infusion at steady state were investigated by mathematical modeling and experimentation. The survival fraction of *P. aeruginosa* was monitored as a function of time and fitted by theoretical equations. The discrimination test and other evidence show that a nonlinear saturable model describes the data better than a linear nonsaturable model. The Nonlinear model has three unknown parameters: the apparent growth rate constant (k_{app}) of bacteria, the bacterial killing rate constant (K'_{sp}) of antibiotics and the Michaelis-Menten

saturation constant (k). The values are: 0.02345 1/min, 0.02623 1/min and 0.05467 $\mu\text{g/ml}$, respectively, for the interaction between piperacillin and *P. aeruginosa*, in the mouse systemic infection model. The survival rate study in neutropenic mice shows that a multiple dosing regimen is 175% more effective than single dosing treatment. Overall, the model can describe and predict both killing and bacterial regrowth phases and therefore has practical usage in antibiotic dosage regimen determinations, e.g. the optimal dosing interval and minimum critical concentration.

23/5/11 (Item 11 from file: 35)
DIALOG(R) File 35:Dissertation Abstracts Online
(c) 1997 UMI. All rts. reserv.

833215 ORDER NO: AAD84-00960
COMBINATION ANTIBIOTIC THERAPY: COMPARISON OF CONSTANT INFUSION
AND INTERMITTENT BOLUS DOSING IN AN IN VITRO KINETIC MODEL AND AN
EXPERIMENTAL ANIMAL MODEL

Author: MORDENTI, JOYCE

Degree: PH.D.

Year: 1983

Corporate Source/Institution: THE UNIVERSITY OF CONNECTICUT
(0056) Source: VOLUME 44/10-B OF DISSERTATION ABSTRACTS
INTERNATIONAL. PAGE 3045. 192 PAGES

Descriptors: HEALTH SCIENCES, PHARMACY

Descriptor Codes: 0572

The influence of mode of administration on the anti-pseudomonal activity of amikacin and ticarcillin was evaluated in an in vitro kinetic model and a neutropenic rat model of peritonitis. Three hundred female Sprague-Dawley rats were rendered neutropenic with cyclophosphamide, infected intraperitoneally with an LD-70 inoculum of *Pseudomonas aeruginosa*, and treated with amikacin and/or ticarcillin for 24 hours. The treatment regimens studied were as follows: amikacin every 2 hours, amikacin every 1/2 hour (approximating continuous infusion), ticarcillin every 3 hours, ticarcillin every 1/2 hour (approximating continuous infusion), both drugs intermittently, both drugs continuously, and combinations of the intermittent and continuous dosing schedules. The dosage regimens were designed to provide the same peak serum concentrations that would be obtained if humans were being treated. Equivalent daily doses of the drugs were given by each mode of administration, producing approximately the same area under the concentration-time curve for the intermittent and the continuous dosing schedules. Based on cumulative mortality at 96 hours, constant infusion of both antibiotics was significantly better than intermittent bolus dosing. Evaluation of blood samples and peritoneal fluid cultures revealed a greater bactericidal effect and increased bacterial filamentation with the dual continuous infusion regimen. An in vitro kinetic model allowed exposure of *P. aeruginosa* to drug concentrations simulating rodent serum antibiotic pharmacokinetics. Treated and untreated bacterial samples were

enumerated by serial dilution plate counts, and time-kill curves were constructed for each 24 hour treatment trial. Based on area under the time-kill curve, combination therapy which included ticarcillin administered continuously was more effective than combination therapy in which the ticarcillin was administered intermittently. Rapid regrowth of the gram-negative rods occurred during the drug-free intervals of the intermittent dosing schedule. The in vitro kinetic model accurately predicted in vivo efficacy for each dosage regimen.

? display sets

Set	Items	Description
S1	8306	FIMBRI?
S2	5871	S1 NOT PY>1992
S3	732	S2(10N) (ISOLAT? OR PURIF?)
S4	118	S3(10N) (RECOMBINANT? OR CLON? OR EXPRESS?) S5
74	RD S4	(unique items)
S6	8393	HAEMOPHILUS INFLUENZA?
S7	4882	S6 NOT PY>1992
S8	8	S7(20N) (FIMBR?)
S9	68	S6(10N) (PILI? OR PILUN? OR PILUS? OR FIMBR?) S10
52	RD S9	(unique items)
S11	35	S10 NOT PY>1993
S12	8351	IMIPENEM?
S13	0	S12(20N)J5
S14	240	S12(5N)BACTERIA?
S15	176	S14 NOT PY>1993
S16	137	RD S15 (unique items)
S17	3919	J5?
S18	8	S17(20N)NEISSERI?
S19	679	NEISSERIA(20N)OUTER?(2W)MEMBRANE?(2W)PROTEIN? S20
0	S19(20N) (DETOXIF?(4W)LPS OR	
	DETOXIF?(2W)LIPOPOLYSACCHARID?) S21	0 (NEUTROPENIC
	RAT?(5N)MODEL?)	
S22	625	NEUTROPEN?(10N)RAT?
S23	542	RD S22 (unique items)
	? s s23(20n) (predict? or correlat?)	
	542	S23
	483797	PREDICT?
	820396	CORRELAT?
S24	15	S23(20N) (PREDICT? OR CORRELAT?)
? t	s24/6/1-15	

24/6/1 (Item 1 from file: 73)

10235663 EMBASE No: 97038790

Predictive value of eosinophilia for neutropenia during clozapine treatment

24/6/2 (Item 2 from file: 73)

9476296 EMBASE No: 95047780

Pharmacokinetic study in carboplatin, cisplatin and 5-fluorouracil regimen for advanced oesophageal cancer

24/6/3 (Item 3 from file: 73)

8847044 EMBASE No: 93150812

Hematologic scoring system in early diagnosis of sepsis in neutropenic newborns

24/6/4 (Item 4 from file: 73)

8743546 EMBASE No: 93047506

Effect of early onset bacterial sepsis or pregnancy induced hypertension (PIH) on neonatal white blood cell and platelet counts in infants less than 1,200 grams

24/6/5 (Item 5 from file: 73)

8293688 EMBASE No: 91325669

Ceftriaxone plus amikacin in neutropenic patients: A report on 100 cases

24/6/6 (Item 6 from file: 73)

8057970 EMBASE No: 91088453

Urinary tract infection in the impaired host

24/6/7 (Item 7 from file: 73)

7767684 EMBASE No: 90195995

The effect of right atrial catheters on infectious complications of chemotherapy in children

24/6/8 (Item 8 from file: 73)

6251414 EMBASE No: 86246477

Correlation of antibiotic synergy in vitro and in vivo: Use of an animal model for neutropenic gram-negative sepsis

24/6/9 (Item 9 from file: 73)

6210783 EMBASE No: 86205844

Combination antibiotic therapy in pediatrics

24/6/10 (Item 10 from file: 73)

6156362 EMBASE No: 86151422

Plasma lactoferrin in patients with neutropenia

24/6/11 (Item 11 from file: 73)

5674227 EMBASE No: 84169893

Hairy cell leukemia. Disease pattern and prognosis

study for a drug, one of the objectives is to investigate a possible causal relationship between the suspect drug and a specific adverse reaction. In that context, two causality assessment problems arise: the Retrodictive one, where each of the adverse events reported is considered separately in order to determine whether the suspect drug was the cause for each of the cases, and the Predictive one, which is the topic of this thesis, where an overall measure of the propensity of the suspect drug causing the adverse event in question is established. Four Bayesian procedures for deriving the predictive distribution of the causal status (drug vs. non-drug) for the next drug user are introduced, differing mainly in the data scheme available. The different data schemes considered, differ with respect to whether the causal agent of the adverse event is assumed known or a subjective probabilistic (retrodictive) assessment for the cause of each adverse event is provided or, simply, making use of the complex nature of the information that appear in all adverse event reports. All procedures are applied to a study linking Mexiletine (an antiarrhythmic drug) therapy with neutropenia (a disease in the blood associated with a mortality rate of about 30%).

23/5/7 (Item 7 from file: 35)
DIALOG(R)File 35:Dissertation Abstracts Online
(c) 1997 UMI. All rts. reserv.

0975758 ORDER NO: AAD87-28912
PHARMACODYNAMIC MODELING OF ANTIMICROBIAL ACTIVITY: PIPERACILLIN
VERSUS PSEUDOMONAS AERUGINOSA

Author: ZHI, JIANGUO

Degree: PH.D

Year: 1987

Corporate Source/Institution: THE UNIVERSITY OF CONNECTICUT
(0056) Source: VOLUME 48/10-B OF DISSERTATION ABSTRACTS
INTERNATIONAL. PAGE 2941. 135 PAGES

Descriptors: HEALTH SCIENCES, PHARMACY

Descriptor Codes: 0572

A pharmacodynamic model describing the interaction of antibiotics with bacteria was developed. Two possible interactions of piperacillin with *Pseudomonas aeruginosa* (ATCC 28753) were tested in vitro in Mueller-Hinton broth at 37°C and in vivo in a mouse systemic infection model. Clinically relevant dosage regimens such as single bolus dosing, multiple doses and constant infusion at steady state were investigated by mathematical modeling and experimentation. The survival fraction of *P. aeruginosa* was monitored as a function of time and fitted by theoretical equations. The discrimination test and other evidence show that a nonlinear saturable model describes the data better than a linear nonsaturable model. The Nonlinear model has three unknown parameters: the apparent growth rate constant (k_{app}) of bacteria, the bacterial killing rate constant (K'_{sp}) of antibiotics and the Michaelis-Menten

saturation constant (k). The values are: 0.02345 1/min, 0.02623 1/min and 0.05467 $\mu\text{g/ml}$, respectively, for the interaction between piperacillin and *P. aeruginosa*, in the mouse systemic infection model. The survival rate study in neutropenic mice shows that a multiple dosing regimen is 175% more effective than single dosing treatment. Overall, the model can describe and predict both killing and bacterial regrowth phases and therefore has practical usage in antibiotic dosage regimen determinations, e.g. the optimal dosing interval and minimum critical concentration.

23/5/11 (Item 11 from file: 35)
DIALOG(R) File 35:Dissertation Abstracts Online
(c) 1997 UMI. All rts. reserv.

833215 ORDER NO: AAD84-00960
COMBINATION ANTIBIOTIC THERAPY: COMPARISON OF CONSTANT INFUSION
AND INTERMITTENT BOLUS DOSING IN AN IN VITRO KINETIC MODEL AND AN
EXPERIMENTAL ANIMAL MODEL

Author: MORDENTI, JOYCE

Degree: PH.D.

Year: 1983

Corporate Source/Institution: THE UNIVERSITY OF CONNECTICUT
(0056) Source: VOLUME 44/10-B OF DISSERTATION ABSTRACTS
INTERNATIONAL. PAGE 3045. 192 PAGES

Descriptors: HEALTH SCIENCES, PHARMACY

Descriptor Codes: 0572

The influence of mode of administration on the anti-pseudomonal activity of amikacin and ticarcillin was evaluated in an in vitro kinetic model and a neutropenic rat model of peritonitis. Three hundred female Sprague-Dawley rats were rendered neutropenic with cyclophosphamide, infected intraperitoneally with an LD-70 inoculum of *Pseudomonas aeruginosa*, and treated with amikacin and/or ticarcillin for 24 hours. The treatment regimens studied were as follows: amikacin every 2 hours, amikacin every 1/2 hour (approximating continuous infusion), ticarcillin every 3 hours, ticarcillin every 1/2 hour (approximating continuous infusion), both drugs intermittently, both drugs continuously, and combinations of the intermittent and continuous dosing schedules. The dosage regimens were designed to provide the same peak serum concentrations that would be obtained if humans were being treated. Equivalent daily doses of the drugs were given by each mode of administration, producing approximately the same area under the concentration-time curve for the intermittent and the continuous dosing schedules. Based on cumulative mortality at 96 hours, constant infusion of both antibiotics was significantly better than intermittent bolus dosing. Evaluation of blood samples and peritoneal fluid cultures revealed a greater bactericidal effect and increased bacterial filamentation with the dual continuous infusion regimen. An in vitro kinetic model allowed exposure of *P. aeruginosa* to drug concentrations simulating rodent serum antibiotic pharmacokinetics. Treated and untreated bacterial samples were

enumerated by serial dilution plate counts, and time-kill curves were constructed for each 24 hour treatment trial. Based on area under the time-kill curve, combination therapy which included ticarcillin administered continuously was more effective than combination therapy in which the ticarcillin was administered intermittently. Rapid regrowth of the gram-negative rods occurred during the drug-free intervals of the intermittent dosing schedule. The in vitro kinetic model accurately predicted in vivo efficacy for each dosage regimen.

? display sets

Set	Items	Description
S1	8306	FIMBRI?
S2	5871	S1 NOT PY>1992
S3	732	S2(10N) (ISOLAT? OR PURIF?)
S4	118	S3(10N) (RECOMBINANT? OR CLON? OR EXPRESS?) S5
74	RD S4	(unique items)
S6	8393	HAEMOPHILUS INFLUENZA?
S7	4882	S6 NOT PY>1992
S8	8	S7(20N) (FIMBR?)
S9	68	S6(10N) (PILI? OR PILUN? OR PILUS? OR FIMBR?) S10
52	RD S9	(unique items)
S11	35	S10 NOT PY>1993
S12	8351	IMIPENEM?
S13	0	S12(20N) J5
S14	240	S12(5N) BACTERIA?
S15	176	S14 NOT PY>1993
S16	137	RD S15 (unique items)
S17	3919	J5?
S18	8	S17(20N) NEISSERI?
S19	679	NEISSERIA(20N) OUTER? (2W) MEMBRANE? (2W) PROTEIN? S20
0	S19(20N) (DETOXIF?(4W) LPS OR	
	DETOXIF?(2W) LIPOPOLYSACCHARID?) S21	0 (NEUTROPENIC
	RAT?(5N) MODEL?)	
S22	625	NEUTROPEN?(10N) RAT?
S23	542	RD S22 (unique items)
? s s23(20n) (predict? or correlat?)		
	542	S23
	483797	PREDICT?
	820396	CORRELAT?
S24	15	S23(20N) (PREDICT? OR CORRELAT?)
? t s24/6/1-15		

24/6/1 (Item 1 from file: 73)
 10235663 EMBASE No: 97038790
 Predictive value of eosinophilia for neutropenia during
 clozapine treatment

24/6/2 (Item 2 from file: 73)

9476296 EMBASE No: 95047780

Pharmacokinetic study in carboplatin, cisplatin and 5-fluorouracil regimen for advanced oesophageal cancer

24/6/3 (Item 3 from file: 73)

8847044 EMBASE No: 93150812

Hematologic scoring system in early diagnosis of sepsis in neutropenic newborns

24/6/4 (Item 4 from file: 73)

8743546 EMBASE No: 93047506

Effect of early onset bacterial sepsis or pregnancy induced hypertension (PIH) on neonatal white blood cell and platelet counts in infants less than 1,200 grams

24/6/5 (Item 5 from file: 73)

8293688 EMBASE No: 91325669

Ceftriaxone plus amikacin in neutropenic patients: A report on 100 cases

24/6/6 (Item 6 from file: 73)

8057970 EMBASE No: 91088453

Urinary tract infection in the impaired host

24/6/7 (Item 7 from file: 73)

7767684 EMBASE No: 90195995

The effect of right atrial catheters on infectious complications of chemotherapy in children

24/6/8 (Item 8 from file: 73)

6251414 EMBASE No: 86246477

Correlation of antibiotic synergy in vitro and in vivo: Use of an animal model for neutropenic gram-negative sepsis

24/6/9 (Item 9 from file: 73)

6210783 EMBASE No: 86205844

Combination antibiotic therapy in pediatrics

24/6/10 (Item 10 from file: 73)

6156362 EMBASE No: 86151422

Plasma lactoferrin in patients with neutropenia

24/6/11 (Item 11 from file: 73)

5674227 EMBASE No: 84169893

Hairy cell leukemia. Disease pattern and prognosis